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Interaction of oligonucleotides condensed into long concatemeric complexes with cancer cells was investigated. Pairs of 24- and 25-mer
oligodeoxyribonucleotides were designed so that they could hybridize and form concatemeric structures. Pre-assembling of the oligonucleotides
into concatemers considerably enhanced their ability to bind to human embryo kidney 293 cells and neuroblastoma IMR-32 cells as compared to
free oligonucleotides. Efficiency of concatemers binding to the cells is improved with increase of the length and concentration of concatemeric
complexes. The obtained results suggest incorporation of pharmacologically active oligonucleotides into concatemeric complexes as an approach
to improvement of their cellular interaction.
© 2006 Elsevier B.V. All rights reserved.Keywords: Oligonucleotide complex; Oligonucleotide delivery; Cellular uptake; Antisense oligonucleotide1. Introduction
Oligonucleotide-based therapeutics – antisense oligonucleo-
tides, ribozymes and siRNAs – open up possibilities to affect
intracellular gene expression and to silence foreign genes of
infectious agents. [1,2]. These gene-targeted therapeutics can
find applications in therapy aimed at a variety of diseases.
However, poor uptake of oligonucleotides by cells remains to be
the main obstacle significantly complicating their clinical
implementation. Considerable efforts have been made to
develop effective delivery systems for oligonucleotides (for
review see [3]). Currently used approaches include the
liposome-based techniques, conjugation of oligonucleotide to
lipid or peptide molecules [4,5], absorption on cationic
polymers and nanoparticles [6,7]. Viral and nonendocytic
delivery systems also have been tested. In spite showing high
delivery efficiency viral vectors currently appear to be rather
dangerous for clinical use because of possible stimulation of
insertational oncogenesis, undesirable immune responses and
toxicities of some viral gene products for host cells [8–12].Abbreviations: DMEM, Dulbecco's modified Eagle's medium; PAAG,
polyacrylamide gel; PAGE, polyacrylamide gel electrophoresis
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doi:10.1016/j.bbamem.2006.03.031Nonviral gene delivery relies mainly on the complexes formed
with cationic liposomes. Many lipoplex formulations have been
studied (for review see [13]), but their in vivo activity is
generally lower as compared to that of viral systems. High
toxicity of some cationic liposomes provides limitation for
wide-spread therapeutic application as well [14–16].
Straightforward approach to improving oligonucleotide
cellular uptake could be recruiting of natural mechanisms
providing transport of extracellular nucleic acids into cells.
Nucleic acids are known to be naturally secreted and absorbed
by cells in living organisms [17–19]. Uptake of nucleic acids by
cells is commonly considered to be mediated by absorptive
endocytosis and fluid phase endocytosis [20,21]. Many reports
have been made on the involvement of cell surface receptors in
nucleic acids transport [22–28]. Attempts to investigate the
mechanism of oligonucleotide uptake and intracellular traffick-
ing were made [29–31]. However, direct mechanism of the
oligonucleotide transport by receptor-mediated process needs
further investigation and to date, no successful research on
delivery of single-stranded oligonucleotides using the proteins
capable of nucleic acids binding have been published. At the
same time, accumulation of oligonucleotides on the cell surface
is claimed to assist their uptake [32]. Also, it was shown that
nucleic acids can bind to lipid surface through magnesium ion
bridges and that this interaction is stimulated by assembly of
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These data suggested that supramolecular complexes of
oligonucleotides capable of multiple interactions with lipid
membranes and cell surface receptors should bind to the cells
more efficiently than individual oligonucleotides. Indeed, it was
found that aggregation of oligonucleotides improves their
delivery efficiency in comparison to monomer oligonucleotides
[33, 35–38].
In the present study, we used two antisense sequences to
design oligonucleotides, which could spontaneously assemble
into long concatemeric complexes. We investigated the in-
teraction of formed concatemeric structures of antisense oligo-
nucleotides with different human cancer cells. It was found that
pre-assembling of oligonucleotides into concatemeric com-
plexes considerably enhances their ability to bind to the cells.
The obtained results suggest simple approach for improving
delivery of oligonucleotide-based therapeutics into cells.2. Materials and methods
2.1. Preparation of concatemers
Oligonucleotides E1 5′-GGA AGT CCA GCC CCATGG ATG ATG-3′, E2
5′-GGC TGG ACT TCC CAT CAT CCATGG-3′, G1 5′-AAT TCC ACT GTA
ATA ATA GGC ATA C-3′, G2 5′-TAC TGT GGA ATT GTATGC CTATTAT-
3′, Stopper E 5′-TTT TCATCATCC ATG G-3′; Stopper G 5′-TTC CGTATG
CCTATTAT-3′ were synthesized by phosphoroamidite method and purified by
HPLC (ICBFM SB RAS). The purity of oligonucleotides analyzed by
electrophoresis in 20% PAAG/8 M Urea gel was 95–98%.
32P-labeling of the oligonucleotides was performed using γ-32P-ATP and
T4-polynucleotide kinase as described in [39]. To obtain concatemer structures,
corresponding oligonucleotide strands (first strand was 32P-labeled) were
incubated at 37 °C for 30 min in appropriate buffer or in DMEM medium in the
absence of serum. The resulting mixture was analyzed in native 10% PAGE run
at 4 °C. After electrophoresis, gels were dried and the images were visualized
usingMolecular Imager FX (BioRad) and counted by Quantity One software. To
evaluate the size of the formed complexes, plasmid pUC18 restriction products
(fragments from 36 to 2686 bp) or 100–1000 bp DNA size marker (Sigma) were
run in parallel and visualized by StainsAll (Sigma) staining.
2.2. Cell culture and binding studies
Studies of oligonucleotide interaction with cells were carried out using
human embryo kidney 293 and neuroblastoma IMR-32 cell lines. The cells were
grown in DMEM supplemented with 10% fetal bovine serum in incubator with
conditions set to 37 °C and 5% CO2. The cells were plated in the 24-well culture
plates (1×105 cells per well) and allowed to adhere overnight. Radiolabeled
concatemers were prepared in serum free DMEM medium as described above
and added to the cells in 250 μl volume. After incubation, the medium withFig. 1. Sequences of the oligonucleotides E andoligonucleotides was removed and cells were washed with 0.5 ml ice-cold
phosphate buffered saline for 2 min, and then lysed in 4M guanidine thiocyanate
solution containing 25 mM sodium citrate and 0.5% N-laurylsarcosine. The
radioactivity of lysed product was measured by scintillation counting, and
resulting values were counted excluding average absorption on the plate. Results
were evaluated as percentage of cell-bound 32P-labeled oligonucleotide. The
final data were represented as means of 3 or 4 independent measurements with
standard deviations as error bars. Statistical significance between groups was
analyzed by Student's t-test. Differences in cell binding for concatemers and
single strand oligonucleotides resulting in P<0.05 were considered to be
statistically significant.3. Results
3.1. Design and formation of oligonucleotide concatemeric
structures
Two antisense oligonucleotides E and G previously used for
downregulation of human mdr1 gene expression were chosen to
develop oligonucleotide pairs capable of forming concatemeric
complexes [40,41]. In order to get stable duplex formation under
physiological conditions (37 °C), initial oligonucleotide
sequences were extended up to 24 or 25 nt. Pairs for 24- and
25-mer antisense oligodeoxyribonucleotides (E1 and G1) were
designed so that the 3′-half sequence of the second strand was
complementary to the 3′-half of the E1 or G1 to provide the
formation of double-stranded DNA complex upon hybridization
(Fig. 1). The principle of oligonucleotide assembly was based on
the half-sliding complementarity of the first and the second
strands sequences. Pairing of one E1 or G1 molecule with E2 or
G2, respectively, was expected to yield 12 bp duplex with 12
unpaired nucleotides at 5′-end of each of the strands. These free
halves of the strands can hybridize with complementary part of
another oligonucleotide molecule and thus induce spontaneous
extension of concatemer structure (see Fig. 1). As a result, long
double-stranded DNA complexes containing nicks at every
12 bp in alternate strands could be formed. To regulate the length
of concatemers, the stopper oligonucleotide molecules (Stopper
E and Stopper G, respectively) were added to the mixture.
Sequences of stopper oligonucleotides represent the shortened
versions of the second strands of oligonucleotide pairs. Hy-
bridization of stopper to the 3′-end of the oligonucleotides E1 or
G1 tail prevents binding of the second strand oligonucleotide
and arrests the extension of the complex (Fig. 1).
Concatemeric complexes of oligonucleotides E and G were
produced by incubation of corresponding oligonucleotides atG and the concatemeric duplex formation.
Fig. 2. Concatemeric complex formation in different buffer solutions
(oligonucleotide G). Lane 1—5′-32P-labeled oligonucleotide G1; lanes 2–5—
concatemers formed by oligonucleotides G1 and G2 (1 μM each) in 50 mM
Tris–HCl, pH 7.3, containing 200 mMKCl, 10 mMMgCl2 (lane 2); in the same
buffer in the absence of magnesium (lane 3); in 50 mM Tris–HCl, pH 7.3 (lane
4), and in H2O (lane 5).
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probes were mixed with loading buffer and immediately applied
into the 10% native PAAG equilibrated at 4 °C. Concatemeric
complexes were prepared in the following solutions: 1) 50 mM
Tris–HCl, pH 7.3, 200 mM KCl, 10 mM MgCl2; 2) 50 mM
Tris–HCl, pH 7.3, 200 mM KCl; 3) 50 mM Tris–HCl, pH 7.3;
4) H2O. The longest concatemers were formed in the solution
containing 10 mM magnesium (Fig. 2).
We studied formation of the concatemeric duplexes at
different concentrations of oligonucleotide strands in the
presence and in the absence of the stopper oligonucleotides in
the solution containing potassium and magnesium at physio-
logical concentrations (Fig. 3). According to the results of gel-
shift analysis, in the absence of stopper oligonucleotides pairs of
oligonucleotides E and G form concatemeric duplexes up toFig. 3. Influence of strands concentrations on the length of concatemeric duplexes f
MgCl2. Lane 1—5′-
32P-labeled oligonucleotide G1; lanes 2, 3, 6, 7—concatemeric st
5, 8, 9—concatemeric duplexes formed in the absence of stoppers; MW—size m
conditions of excess of the second strand—E2 (E1—32P-labeled).2000 bp in length. The effect of oligonucleotides concentrations
on the concatemer formation was also investigated (Fig. 3, lanes
10–15). At equimolar concentrations of oligonucleotide strands
in the reaction mixture, the main pool of the concatemers is
represented by complexes above 200 bp in size. Excess of one
of the strands results in formation of shorter duplexes. These
results are in agreement with the previously published data on
the nicked DNA duplexes formation, according to which
equimolar stoichiometry of oligonucleotide components is
preferable for the formation of longer nicked double-stranded
structures [42].
As it could be expected, addition of the stopper resulted in
formation of short complexes. Association of E oligonucleo-
tides revealed non-uniform formation of concatemeric struc-
tures resulting in different intensity of bands seen in Fig. 3,
lanes 6, 7, 12–15. This effect can be explained by more
effective hybridization of one of the 12 nt oligonucleotide
halves to its complementary sequence due to the asymmetry in
G:C pairs distribution in the E oligonucleotide sequence.
3.2. Interaction of oligonucleotide concatemers with cells
To explore the influence of oligonucleotides association into
concatemeric complexes on their interaction with eukaryotic
cells 32P-labeled concatemers were incubated with different
human cancer cell lines. Experiments with 293—human
embryo kidney cells and IMR-32—neuroblastoma cells
demonstrated enhanced cellular binding of oligonucleotides in
concatemeric complexes (1 μM concentration in the medium) as
compared to single-stranded oligonucleotides at the same
concentration (Fig. 4). The data show reliable increase of
binding (2–4 times) of concatemers E and G with 293 cells and
concatemers G with IMR-32 cells as compared to single-
stranded oligonucleotides, while the difference in concatemersormed in solution containing 50 mM Tris–HCl, pH 7.3, 200 mM KCl, 10 mM
ructures formed by E and G oligonucleotides in the presence of stoppers; lanes 4,
arker. Lanes 11–15—formation of concatemers of oligonucleotides E under
Fig. 4. Binding of oligonucleotides E1 and G1 and concatemers, formed by E1
and E2 or G1 and G2 oligonucleotides with 293 and IMR-32 cells. Cells were
incubated with oligonucleotides for 3 h, the concentration of oligonucleotides
was 1 μM.
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the limits of standard deviation. In contrast, binding of
concatemeric complexes with KB-3-1—epidermoid carcinoma
and HeLa—ovarian carcinoma cells did not exceed the level of
binding for single-stranded oligonucleotides (data not shown).
Thus, the effect of enhanced binding for concatemeric
complexes is cell type-dependent.
The influence of the concentration of concatemers and free
oligonucleotides (oligonucleotide E) on the binding with 293
cells was investigated. Equimolar concentrations of oligonu-
cleotide strands in the absence of the stopper were used. It is
seen (Fig. 5A) that in contrast to monomer oligodeoxyribonu-
cleotides, the concatemeric oligonucleotide complexes demon-Fig. 5. Binding of oligonucleotide E1 and concatemers formed by equimolar
mixture of oligonucleotides E1 and E2 (in the absence of the Stopper E) with
embryo kidney 293 cells. (A) Concentration dependences of binding of the
oligonucleotide E1 and corresponding concatemer complex after 3 h incubation
with cells. (B) Kinetics of the oligonucleotide and concatemer binding to the
cells. Oligonucleotides concentration in the medium was 1 μM.strate more efficient cellular binding at higher oligonucleotide
concentrations within the interval 0.01–1 μM.
Time course of oligonucleotides and concatemers (1 μM
concentrations of the strands) binding with 293 cells is shown in
Fig. 5B. The results of the experiments revealed that binding of
the free oligonucleotide is not increased after 30 min of
incubation. In contrast, the amount of cell-bound oligonucleo-
tides assembled into concatemeric structures is slowly increased
during 3-h incubation, showing that the interaction of these
complexes with the cells is characterized by slow kinetics (Fig.
5B).
The length of the concatemers formed upon hybridization of
oligonucleotides was shown to depend on the oligonucleotide
components concentration (Fig. 3). We compared efficiency of
cellular binding of concatemeric complexes of different size
formed by oligonucleotides E (Fig. 6). The most efficient
binding was observed for the largest complexes formed when
the strands were presented at equimolar concentrations. Cell
binding of short concatemers, formed in the presence of stopper
or under the excess of one of the strands, was comparable with
the binding of single-stranded oligonucleotides or the difference
was not statistically reliable. In 1 μM equimolar solution of
oligonucleotides E1 and E2 only a fraction of the oligonucleo-
tides is involved in the complexes (Fig. 6B, lane 1). As it was
shown that cellular binding efficiency of the single-stranded
oligonucleotides even at higher concentration (Fig. 6, lane 6) is
lower than binding of mixture containing concatemers, it can be
concluded that the main contribution to the increased bindingFig. 6. (A) Influence of the size of concatemeric duplexes formed by
oligonucleotides E1, E2 and Stopper E on their interaction with 293 cells. (B)
Analysis of concatemer length (in the medium after incubation with the cells) by
native PAAG electrophoresis, 32P-label is located at 5′-end of E1. Lane 1—
1 μM E1 and E2; lane 2—1 μM E1, E2 and Stopper E; lane 3—1 μM E1 and E
2, 2 μMStopper E; lane 4—5 μME1 and 30 μME2; lane 5—10 μME1, E2 and
Stopper E; lane 6—10 μM E1.
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length of the concatemeric complexes was analyzed by gel
electrophoresis prior and after the incubation with the cells.
Long concatemers were shown to be stable for at least 3 h
administration to the cells (see Fig. 6B).
4. Discussion
Aggregation of oligonucleotides facilitates their cellular
binding and uptake. Therefore, we addressed the question
whether the formation of concatemeric complexes improves
the oligonucleotide binding by the eukaryotic cells. We
designed concatemeric oligonucleotide structures built of
half-slide complementary oligonucleotide pairs. Hybridiza-
tion of overlapping oligonucleotide strands results in
formation of double-stranded structure with periodic nicks
in their backbone, which increase the flexibility of the
formed long DNA duplex [42]. Due to efficient stacking
between adjacent oligonucleotides the concatemer complex
is thermodynamically more stable than the corresponding
duplexes formed by oligonucleotides of the same length.
Contiguous hybridization leads to partial removal of fraying
at the adjacent oligonucleotide ends, and the effect of the
direct stacking of the terminal base pairs in the duplex
junction provides more auspicious conditions for hybridiza-
tion of the next oligonucleotide molecule thus contributing
to the stability of long concatemeric complexes [43–45].
The choice of oligonucleotides to perform the formation of
concatemeric complexes follows several requirements. Initial
sequence of the first strand is determined by the biological
target sequence of the oligonucleotide. Free oligonucleotide
halves should be approximately equal in length and melting
temperatures (i.e., A:T/G:C pair distribution) to obtain uniform
extension of the duplex. In our study we observed that
misbalance in only one G:C pair led to noticeable change in
the character of concatemeric duplex pattern especially at low
concentrations of oligonucleotide components (Fig. 2). Self-
complementarity and secondary structures should be avoided
for both oligonucleotide strands. Moreover, possibility of
undesirable sliding hybridization between oligonucleotides
should be excluded because it might lead to alternative
complexes formation (including bulges and gaps) and thus
disrupt the appropriate extension of concatemeric duplex. In
spite of this seeming complexity, the design of concatemeric
oligonucleotides turns out to be easier as at least some of this
requirements (particularly, lack of self-complementary struc-
tures) are inevitable for the choice of antisense sequences.
Desired oligonucleotide also can be extended according to the
target mRNA sequence to obtain more stable complexes. In any
case, the efficiency of concatemeric complex formation and
influence of such sequence extension on its biological activity
should be verified individually.
We found that concatemeric oligonucleotide structures bind
to 293 and IMR-32 cells considerably better then monomer
oligonucleotides. Concatemers interaction with cells is more
efficient at higher oligonucleotides concentration, which is not
the case for the single-stranded oligonucleotides at the usedconcentrations. Apparently, this phenomenon is a result of more
efficient formation of long complexes at higher concentrations
of oligonucleotide components in the medium.
The slow kinetics of concatemer binding to the cells can be
explained by implying different mechanisms of absorption by
cells for single-stranded oligonucleotides and concatemers.
Considerable binding increase for the longest concatemer
molecules consisting of many copies of assembling oligonu-
cleotides suggests that oligonucleotide uptake in the supramo-
lecular condensed form leads to the improvement of delivery
efficiency. It is possible that the rise of local concentration of
oligonucleotides provided by association into concatemers
leads to the enhancement of penetration through the cell
membrane. As we did not address the mechanism of the cell
binding process, it remains questionable whether the effect of
enhanced concatemer binding is due to formation of more
condensed oligonucleotide particles on the cell surface or due to
higher efficiency of interaction with cellular receptors. Cell type
specificity of the phenomenon may support the concept of the
involvement of cell surface proteins.
Concentration of oligonucleotides at the cell surface turns
out to be the major factor determining efficiency of cellular
uptake of oligonucleotides. The phenomenon of enhanced
binding of concatemeric oligonucleotide structures by cells
suggests an approach to improving cellular delivery of
oligonucleotide therapeutics. This strategy could be applicable
for antisense oligonucleotides and siRNA, which can fulfill the
requirements to be assembled in concatemer complexes.
Oligonucleotide concatemers are easy to prepare and were
shown to be stable at physiological concentrations of salts and
during incubation with cell culture. Incorporation of therapeutic
oligonucleotides in concatemeric structures provides an addi-
tional advantage—protection of oligonucleotide molecules
from cellular nucleases, which readily destroy single-stranded
oligonucleotides. Whether this approach will provide enhanced
oligonucleotide delivery to their intercellular targets and
improve biological activity of oligonucleotide therapeutics
remains to be investigated.
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